[Summary] 一家临床阶段的全球性生物制药公司
关于阿诺医药
阿诺医药(纳斯达克股票代码:ANL)是一家临床阶段的全球性生物制药公司,专注于“全球新”肿瘤药物研发,在中美两地均设有研发及临床运营中心。公司集结了经验丰富的领导和研发团队,建立了差异化的肿瘤产品管线,并与多家知名头部制药公司合作,加速药物发现和开发。 我们致力于成为打造“全球新”肿瘤药物的创新型研发企业,以更优良的治疗方式惠及中国乃至全球患者。
依托中美双中心研发布局,我们已构建起一条聚焦两个核心领域的有影响力的研发管线: ①RAS驱动肿瘤的靶向治疗策略:包括AN9025(口服泛RAS(ON) 抑制剂),以及AN4035(靶向 CEACAM5 的新型ADC,将高效泛 RAS(ON) 抑制剂精准递送至肿瘤);②下一代肿瘤免疫疗法:包括 AN8025(由 αPD-L1 × CD86 变体 × LAG3 变体构成的三功能融合蛋白,调节 T 细胞与抗原呈递细胞),以及AN4005(口服小分子 PD-L1 抑制剂)。
欲了解更多,请访问*。
What does 杭州阿诺生物医药科技有限公司 require? Who is 阿诺医药 hiring? 阿诺医药 recruitment: 财务/审计/统计类占比最多占35.5%,其次是生物/制药/化工/环保类占25.8%. What education can get in at 阿诺医药? 本科占比最多占41.9%,其次是硕士占35.5%. High education required at 阿诺医药? 硕士占35.5%,博士占16.1%. Work experience required at 阿诺医药? 不限占比最多占41.9%,其次是3-5年占32.3%. Where are the job locations at 阿诺医药? 杭州占比最多占90.3%,其次是上海占9.7%. Based on job postings from the past year, for reference only.
Featuring 203 companies ,4 followers
Featuring 29 companies ,1 followers
Featuring 29 companies ,1 followers
Featuring 19 companies
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows